TRAVEL III
2026
Transcatheter Tricuspid Valve Replacement with the LuX-Valve Plus System vs. Medical Therapy for Severe TR (TRAVEL III)
In patients with severe tricuspid regurgitation, transcatheter tricuspid valve replacement with the LuX-Valve Plus system plus optimal medical therapy improved the 6-month composite endpoint compared with medical therapy alone.
Ergebnis
Primärer Endpunkt: Composite endpoint at 6 months; major adverse events at 30 days (per the probable registration)
The composite endpoint event rate difference was 78.1% (P<0.001), with TTVR plus optimal medical therapy significantly better than medical therapy alone. Procedural success was 98.7%.
- Unterthema
- Transcatheter tricuspid replacement
- Design
- Prospective, multicentre randomised trial in China; transcatheter tricuspid valve replacement with the LuX-Valve Plus system plus optimal medical therapy versus optimal medical therapy alone, in patients aged 65 or older with severe or greater TR, NYHA III-IV, at high surgical risk
- Eingeschlossen
- 118 Patienten
- Quelle
- Ge J, et al. Presented at TCT 2026, 1 November. Jenscare Scientific voluntary announcement (09877.HK), 2 November 2026. Not yet published.
Diskussion & Kritik
The trial is randomised and multicentre, and the sponsor reports a large difference in the composite endpoint in favour of valve replacement at 6 months. The announcement gives no arm values, no confidence interval, no components of the composite and no safety figures, so the size and drivers of the effect cannot be judged. Follow-up is only 6 months in 118 patients, the comparator is medical therapy alone, and the announcement does not say whether the trial was blinded. The only source is the sponsor's own announcement, and the trial is not yet published.